BioMed Central | Articles which cite: Production of infectious human immunodeficiency virus type 1 does not require depletion of APOBEC3G from virus-producing cells.

Log on / register
Feedback | Support | My details

home journals A-Z subject areas advanced search authors reviewers libraries about my BioMed Central

Production of infectious human immunodeficiency virus type 1 does not require depletion of APOBEC3G from virus-producing cells.
Kao S, Miyagi E, Khan MA, Takeuchi H, Opi S, Goila-Gaur R, Strebel K
Retrovirology 2004, 1:27
[Full text] [PubMed] [Related articles] [Cited on BioMed Central]

printer friendly

to [Help]

PubMed Central articles that cite the above article:

1.	Population level analysis of human immunodeficiency virus type 1 hypermutation and its relationship with APOBEC3G and vif genetic variation. Pace C, Keller J, Nolan D, James I, Gaudieri S, Moore C, Mallal S J Virol 2006 Sep, 80:9259-69 [PubMed Central] [PubMed] [Related articles]
2.	Polymorphisms of CUL5 are associated with CD4+ T cell loss in HIV-1 infected individuals. An P, Duggal P, Wang LH, O'Brien SJ, Donfield S, Goedert JJ, Phair J, Buchbinder S, Kirk GD, Winkler CA PLoS Genet 2007 Jan 26, 3:e19 [PubMed Central] [PubMed] [Related articles]
3.	Newly synthesized APOBEC3G is incorporated into HIV virions, inhibited by HIV RNA, and subsequently activated by RNase H. Soros VB, Yonemoto W, Greene WC PLoS Pathog 2007 Feb, 3:e15 [PubMed Central] [PubMed] [Related articles]
4.	* Unable to retrieve article 17291161 * [PubMed Central] [PubMed] [Related articles]
5.	Human immunodeficiency virus type 1 Vif inhibits packaging and antiviral activity of a degradation-resistant APOBEC3G variant. Opi S, Kao S, Goila-Gaur R, Khan MA, Miyagi E, Takeuchi H, Strebel K J Virol 2007 Aug, 81:8236-46 [PubMed Central] [PubMed] [Related articles]
6.	Vif counteracts a cyclophilin A-imposed inhibition of simian immunodeficiency viruses in human cells. Takeuchi H, Buckler-White A, Goila-Gaur R, Miyagi E, Khan MA, Opi S, Kao S, Sokolskaja E, Pertel T, Luban J, Strebel K J Virol 2007 Aug, 81:8080-90 [PubMed Central] [PubMed] [Related articles]
7.	T cells contain an RNase-insensitive inhibitor of APOBEC3G deaminase activity. Thielen BK, Klein KC, Walker LW, Rieck M, Buckner JH, Tomblingson GW, Lingappa JR PLoS Pathog 2007 Sep 21, 3:1320-34 [PubMed Central] [PubMed] [Related articles]
8.	Production of infectious virus and degradation of APOBEC3G are separable functional properties of human immunodeficiency virus type 1 Vif. Kao S, Goila-Gaur R, Miyagi E, Khan MA, Opi S, Takeuchi H, Strebel K Virology 2007 Dec 20, 369:329-39 [PubMed Central] [PubMed] [Related articles]
9.	Enzymatically active APOBEC3G is required for efficient inhibition of human immunodeficiency virus type 1. Miyagi E, Opi S, Takeuchi H, Khan M, Goila-Gaur R, Kao S, Strebel K J Virol 2007 Dec, 81:13346-53 [PubMed Central] [PubMed] [Related articles]
10.	Identification of an APOBEC3G binding site in human immunodeficiency virus type 1 Vif and inhibitors of Vif-APOBEC3G binding. Mehle A, Wilson H, Zhang C, Brazier AJ, McPike M, Pery E, Gabuzda D J Virol 2007 Dec, 81:13235-41 [PubMed Central] [PubMed] [Related articles]
11.	* Unable to retrieve article 17892323 * [PubMed Central] [PubMed] [Related articles]
12.	Vpr14-88-Apobec3G fusion protein is efficiently incorporated into Vif-positive HIV-1 particles and inhibits viral infection. Ao Z, Yu Z, Wang L, Zheng Y, Yao X PLoS One 2008, 3:e1995 [PubMed Central] [PubMed] [Related articles]
13.	HIV-1 Vif promotes the formation of high molecular mass APOBEC3G complexes. Goila-Gaur R, Khan MA, Miyagi E, Kao S, Opi S, Takeuchi H, Strebel K Virology 2008 Mar 1, 372:136-46 [PubMed Central] [PubMed] [Related articles]
14.	APOBEC3G is degraded by the proteasomal pathway in a Vif-dependent manner without being polyubiquitylated. Dang Y, Siew LM, Zheng YH J Biol Chem 2008 May 9, 283:13124-31 [PubMed Central] [PubMed] [Related articles]
15.	* Unable to retrieve article 18326044 * [PubMed Central] [PubMed] [Related articles]
16.	APOBEC3G and APOBEC3F require an endogenous cofactor to block HIV-1 replication. Han Y, Wang X, Dang Y, Zheng YH PLoS Pathog 2008 Jul, 4:e1000095 [PubMed Central] [PubMed] [Related articles]
17.	Differential sensitivity of "old" versus "new" APOBEC3G to human immunodeficiency virus type 1 vif. Goila-Gaur R, Khan MA, Miyagi E, Strebel K J Virol 2009 Jan, 83:1156-60 [PubMed Central] [PubMed] [Related articles]
18.	Regulation of APOBEC3 proteins by a novel YXXL motif in human immunodeficiency virus type 1 Vif and simian immunodeficiency virus SIVagm Vif. Pery E, Rajendran KS, Brazier AJ, Gabuzda D J Virol 2009 Mar, 83:2374-81 [PubMed Central] [PubMed] [Related articles]

This article is also cited by 7 articles in BioMed Central

printer friendly

to [Help]

Terms and Conditions Privacy statement Information for advertisers Jobs at BMC Contact us